Hugel Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Hugel yıllık ortalama 16.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.2% annual. Gelirler growing yılda ortalama 11.9% oranında artmaktadır. Hugel'in özkaynak karlılığı 14.6% ve net marjı 32.4%'dir.

Anahtar bilgiler

16.9%

Kazanç büyüme oranı

19.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.7%
Gelir büyüme oranı	11.9%
Özkaynak getirisi	14.6%
Net Marj	32.4%
Sonraki Kazanç Güncellemesi	06 Nov 2024

Yakın geçmiş performans güncellemeleri

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Mar 29

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29

Recent updates

Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet

Oct 19

An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

Sep 13

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

Mar 19

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Feb 25

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Feb 04

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Jan 17

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

Dec 14

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Nov 24

Gelir ve Gider Dağılımı

Hugel nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

KOSDAQ:A145020 Gelir, gider ve kazançlar (KRW Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	343,494	111,174	106,754	8,952
31 Mar 24	329,626	97,506	111,930	9,927
31 Dec 23	319,700	93,076	109,470	11,015
30 Sep 23	316,245	78,490	112,434	14,330
30 Jun 23	302,105	66,435	111,266	14,722
31 Mar 23	284,412	59,834	104,165	14,902
31 Dec 22	281,675	60,558	94,514	15,078
30 Sep 22	253,838	62,665	82,959	13,833
30 Jun 22	235,499	55,511	72,126	13,284
31 Mar 22	229,679	54,981	65,360	12,366
31 Dec 21	231,859	56,506	61,675	12,624
30 Sep 21	241,634	64,582	59,823	11,853
30 Jun 21	243,369	54,222	56,151	14,060
31 Mar 21	233,604	54,615	51,135	15,879
31 Dec 20	211,038	41,992	49,326	15,741
30 Sep 20	197,629	39,728	50,507	14,950
30 Jun 20	194,699	39,910	54,203	12,849
31 Mar 20	196,707	36,815	57,970	11,034
31 Dec 19	204,568	44,612	61,520	10,226
30 Sep 19	209,360	47,993	66,022	10,433
30 Jun 19	193,154	60,763	68,360	9,514
31 Mar 19	185,732	64,104	65,752	8,823
31 Dec 18	182,392	69,736	60,964	7,750
30 Sep 18	173,688	75,552	49,981	6,930
30 Jun 18	180,322	69,985	39,374	6,653
31 Mar 18	183,613	73,918	34,202	7,038
31 Dec 17	182,085	72,827	30,933	6,922
30 Sep 17	169,778	67,665	26,912	6,878
30 Jun 17	161,011	63,022	26,718	5,811
31 Mar 17	145,786	56,096	25,919	4,436
31 Dec 16	124,189	43,273	25,187	4,065
30 Sep 16	108,883	36,540	23,350	3,372
30 Jun 16	94,231	73,093	22,303	2,919
31 Mar 16	80,098	39,216	18,795	3,884
31 Dec 15	65,066	33,929	16,425	3,156
30 Sep 15	59,328	33,924	14,940	3,087
30 Jun 15	49,887	-12,904	11,963	3,616
31 Dec 14	40,350	13,150	10,652	1,942
31 Dec 13	29,170	7,307	7,175	2,220

Kaliteli Kazançlar: A145020 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: A145020 'nin mevcut net kar marjları (32.4%) geçen yılın (22%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A145020 şirketinin kazancı son 5 yılda yılda 16.9% oranında arttı.

Büyüme Hızlandırma: A145020 'un son bir yıldaki kazanç büyümesi ( 67.3% ) 5 yıllık ortalamasını (yıllık 16.9% ) aşıyor.

Kazançlar vs. Sektör: A145020 geçen yılki kazanç büyümesi ( 67.3% ) Biotechs sektörünün 6.1% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: A145020 'nin Özsermaye Getirisi ( 14.6% ) düşük olarak değerlendiriliyor.

Hugel Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Hugel, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Hugel, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Hugel, Inc. to Report Q1, 2024 Final Results on May 09, 2024

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Hugel, Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Recent updates

Hugel, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 16%

An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

Consensus EPS estimates increase by 13%

Price target increased by 7.2% to ₩279,444

There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Investor sentiment deteriorates as stock falls 16%

Now 25% undervalued

Hugel, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Price target increased by 13% to ₩254,889

Investor sentiment improves as stock rises 21%

Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Now 21% undervalued

Now 22% undervalued

Hugel, Inc. to Report Q1, 2024 Final Results on May 09, 2024

Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Now 23% undervalued

Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Investor sentiment improves as stock rises 19%

Price target increased by 8.7% to ₩201,750

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Consensus EPS estimates increase by 38%

Price target increased by 8.1% to ₩172,571

Hugel Resubmits BLA for Its Botulinum Toxin, Letybo to the U.S. Fda

Price target decreased by 8.8% to ₩159,250

Hugel, Inc. (KOSDAQ:A145020) acquired additional 3.13% stake in Across Co., Ltd for KRW 9.385 billion.

Investor sentiment deteriorates as stock falls 18%

Price target increased by 7.3% to ₩189,714

Investor sentiment deteriorates as stock falls 18%

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Now 29% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

Less than half of directors are independent

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,875

Hugel, Inc. Appoints Brent Saunders to its Board of Director

No independent directors

Hugel, Inc. (KOSDAQ:A145020) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Price target decreased to ₩214,889

Investor sentiment deteriorated over the past week

Price target decreased to ₩238,333

Consensus EPS estimates fall by 10%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

New 90-day low: ₩174,400

Hugel, Inc. Announces Approval to Launch of Letybo 50U in Prc Market

Hugel, Inc., Annual General Meeting, Mar 26, 2021

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Hugel, Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021

Investor sentiment improved over the past week

New 90-day high: ₩224,700

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Price target raised to ₩251,818

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

New 90-day low: ₩175,600

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Price target raised to ₩241,515

Price target raised to ₩227,788